本文报告了对一个患有常染色体显性多囊肾病的转移性前列腺癌患者进行前列腺特异性膜抗原基因治疗（RLT）的剂量评估。方法：该患者在住院期间，在6个RLT周期中每次接受血液透析。我们使用像素剂量学和血液采样进行剂量计算。结果：患者对RLT有良好的反应，其前列腺特异性抗原水平从298 ng/mL降至7.1 ng/mL。每个周期的剂量范围为：颌咽腺0.19 ~ 0.4 Gy/GBq，颌下腺0.14 ~ 0.28 Gy/GBq，肾脏0.03 ~ 0.11 Gy/GBq，红骨髓0.10 ~ 0.15 Gy/GBq。结论：本病例表明，在接受血液透析的慢性肾脏病患者中，[177Lu]Lu-PSMA基因治疗可成功且安全应用。© 2023年由核医学与分子影像学学会出版

We report the dosimetric evaluation of prostate-specific membrane antigen-based radioligand therapy (RLT) for metastatic prostate cancer in a patient with autosomal-dominant polycystic kidney disease. Methods: The patient received hemodialysis during each of 6 RLT cycles while staying as an inpatient. We used voxel dosimetry and blood sampling for the dose calculation. Results: The patient responded well to the RLT, as indicated by the prostate-specific antigen level decreasing from 298 to 7.1 ng/mL. The doses per cycle ranged from 0.19 to 0.4 Gy/GBq for the parotid gland, 0.14 to 0.28 Gy/GBq for the submandibular gland, 0.03 to 0.11 Gy/GBq per kidney, and 0.10 to 0.15 Gy/GBq for the red bone marrow. Conclusion: This case suggests that [177Lu]Lu-PSMA-based RLT can be applied successfully and safely to a patient with chronic kidney disease undergoing hemodialysis.© 2023 by the Society of Nuclear Medicine and Molecular Imaging.